COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis
USA - NASDAQ:COLL - US19459J1043 - Common Stock
45.98 USD
-0.4 (-0.86%)
45.98 USD
0 (0%)
Taking everything into account, COLL scores 6 out of 10 in our fundamental rating. COLL was compared to 192 industry peers in the Pharmaceuticals industry. COLL scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on COLL. This makes COLL very considerable for value investing!
1. Profitability
1.1 Basic Checks
COLL had positive earnings in the past year.
COLL had a positive operating cash flow in the past year.
Of the past 5 years COLL 4 years were profitable.
In the past 5 years COLL always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.64%, COLL belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
With an excellent Return On Equity value of 21.27%, COLL belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
COLL has a Return On Invested Capital of 9.10%. This is amongst the best in the industry. COLL outperforms 86.98% of its industry peers.
The Average Return On Invested Capital over the past 3 years for COLL is below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
COLL has a Profit Margin of 7.72%. This is amongst the best in the industry. COLL outperforms 83.85% of its industry peers.
In the last couple of years the Profit Margin of COLL has declined.
COLL has a Operating Margin of 20.74%. This is amongst the best in the industry. COLL outperforms 87.50% of its industry peers.
In the last couple of years the Operating Margin of COLL has grown nicely.
The Gross Margin of COLL (57.22%) is better than 66.67% of its industry peers.
In the last couple of years the Gross Margin of COLL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), COLL is creating some value.
Compared to 1 year ago, COLL has less shares outstanding
The number of shares outstanding for COLL has been reduced compared to 5 years ago.
COLL has a better debt/assets ratio than last year.
2.2 Solvency
COLL has an Altman-Z score of 1.46. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
COLL has a better Altman-Z score (1.46) than 61.98% of its industry peers.
The Debt to FCF ratio of COLL is 2.79, which is a good value as it means it would take COLL, 2.79 years of fcf income to pay off all of its debts.
COLL's Debt to FCF ratio of 2.79 is amongst the best of the industry. COLL outperforms 90.63% of its industry peers.
COLL has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of COLL (2.71) is worse than 81.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.46 |
ROIC/WACC1.03
WACC8.81%
2.3 Liquidity
COLL has a Current Ratio of 1.36. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.36, COLL is doing worse than 72.92% of the companies in the same industry.
A Quick Ratio of 1.27 indicates that COLL should not have too much problems paying its short term obligations.
The Quick ratio of COLL (1.27) is worse than 69.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.73% over the past year.
Measured over the past years, COLL shows a very strong growth in Earnings Per Share. The EPS has been growing by 154.78% on average per year.
COLL shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.34%.
COLL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.31% yearly.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -2.05% on average per year.
Based on estimates for the next years, COLL will show a small growth in Revenue. The Revenue will grow by 3.11% on average per year.
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-2.05%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.11%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.39, the valuation of COLL can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 94.79% of the companies listed in the same industry.
COLL is valuated cheaply when we compare the Price/Earnings ratio to 25.89, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 5.41, the valuation of COLL can be described as very cheap.
95.83% of the companies in the same industry are more expensive than COLL, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, COLL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.39 | ||
| Fwd PE | 5.41 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, COLL is valued cheaper than 97.92% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 94.79% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.01 | ||
| EV/EBITDA | 4.79 |
4.3 Compensation for Growth
COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
COLL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y14.84%
EPS Next 3Y5.61%
5. Dividend
5.1 Amount
COLL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45.98
-0.4 (-0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.73%
Inst Owner Change0.4%
Ins Owners1.56%
Ins Owner Change-2.1%
Market Cap1.45B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.82
Price Target45.49 (-1.07%)
Short Float %16.91%
Short Ratio13.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)0%
PT rev (3m)0.9%
EPS NQ rev (1m)1.52%
EPS NQ rev (3m)14.25%
EPS NY rev (1m)7.69%
EPS NY rev (3m)29.1%
Revenue NQ rev (1m)2.44%
Revenue NQ rev (3m)5.37%
Revenue NY rev (1m)-0.67%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.39 | ||
| Fwd PE | 5.41 | ||
| P/S | 1.91 | ||
| P/FCF | 5.01 | ||
| P/OCF | 4.98 | ||
| P/B | 5.27 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.79 |
EPS(TTM)7.19
EY15.64%
EPS(NY)8.51
Fwd EY18.5%
FCF(TTM)9.18
FCFY19.97%
OCF(TTM)9.24
OCFY20.09%
SpS24.03
BVpS8.72
TBVpS-18.92
PEG (NY)0.16
PEG (5Y)N/A
Graham Number37.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.46 |
F-Score7
WACC8.81%
ROIC/WACC1.03
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-2.05%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.11%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year149%
EBIT Next 3Y27.45%
EBIT Next 5Y16.73%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 7 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.